The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -70.43%.However, over the last six months, we can see a stronger performance of -77.89%. Over the last 30 days, the price of ACRV has leaped by -31.80%. And in the last five days, it has fallen by -1.66%.
Acrivon Therapeutics Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $10.29 on 05/03/24 and a low of $1.30 for the same time frame on 04/09/25.
52-week price history of ACRV Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Acrivon Therapeutics Inc’s current trading price is -82.70% away from its 52-week high, while its distance from the 52-week low is 36.92%. The stock’s price range during this period has varied between$1.30 and $10.29. The Acrivon Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 14.82 million for the day, a figure considerably higher than their average daily volume of 0.18 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Acrivon Therapeutics Inc (ACRV) has experienced a quarterly decline of -67.34% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 55.81M and boasts a workforce of 78 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.0164, with a change in price of -5.7500. Similarly, Acrivon Therapeutics Inc recorded 278,613 in trading volume during the last 100 days, posting a change of -76.46%.
ACRV’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ACRV stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.01.
ACRV Stock Stochastic Average
As of today, Acrivon Therapeutics Inc’s raw stochastic average for the last 50 days stands at 9.83%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 38.52%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 34.09% and 26.25%, respectively.
